Science and Retraction Watch reporting highlighted a fatal gene-editing case in China involving an experimental brain-directed CRISPR base editor, raising questions about ethics and clinical oversight. The investigation describes a six-year-old girl, “Mei,” who developed fever and signs of kidney damage after receiving a viral-delivered base editor and died within a week. The account says the treatment was developed through an academic team and that preclinical evidence in mice and nonhuman primates suggested it worked, but that the clinical arrangements were unusually risky or atypical. The most likely cause in a hospital report was an immune reaction to the viral vectors used for delivery. The story emphasizes that Mei’s death was not publicly disclosed and that her family, which paid for development, is now seeking accountability. The trial’s outcome has reignited scrutiny of how gene-editing protocols, consent, vector safety, and monitoring are governed in early-stage human use. Regulators and institutional review boards will face renewed pressure to define clearer guardrails for innovative gene-editing interventions, particularly those using viral delivery systems.